NEK2 Is an Effective Target for Cancer Therapy With Potential to Induce Regression of Multiple Human Malignancies

Cancer is characterized by uncontrolled cell proliferation due to the aberrant activity of various proteins. Cell cycle-related proteins are thought to be important in several functions, such as proliferation, invasion and drug resistance in human malignancies. Never in mitosis gene A-related kinase 2 (NEK2) is a cell cycle-related protein. NEK2 is highly expressed in various tumor types and cancer cell lines. NEK2 expression is correlated with rapid relapse and poor outcome in multiple cancer types. Several researchers have demonstrated that NEK2 inhibition results in anticancer effects against many types of cancers, both in vitro and in vivo. Recent research strongly indicates the advantages of NEK2-targeted therapy for cancer. This review focuses on the current understanding of NEK2 in cancer and the rationale of a xenograft cancer model for cancer treatment. A possible therapeutic strategy, such as inhibitor and nucleic acid medicine targeting of NEK2, is also discussed.

[1]  P. Sicinski,et al.  Cell cycle proteins as promising targets in cancer therapy , 2017, Nature Reviews Cancer.

[2]  Manyi Yang,et al.  Increased NEK2 in hepatocellular carcinoma promotes cancer progression and drug resistance by promoting PP1/Akt and Wnt activation. , 2016, Oncology reports.

[3]  M. Nagino,et al.  Nek2 siRNA therapy using a portal venous port–catheter system for liver metastasis in pancreatic cancer , 2016, Cancer science.

[4]  Hai-Meng Zhou,et al.  NEK2 regulates stem-like properties and predicts poor prognosis in hepatocellular carcinoma. , 2016, Oncology reports.

[5]  D. Hose,et al.  FOXM1 is a therapeutic target for high-risk multiple myeloma , 2016, Leukemia.

[6]  Yan-fen Fang,et al.  Targeting NEK2 as a promising therapeutic approach for cancer treatment , 2016, Cell cycle.

[7]  Y. Morine,et al.  High NEK2 Expression Is a Predictor of Tumor Recurrence in Hepatocellular Carcinoma Patients After Hepatectomy. , 2016, Anticancer Research.

[8]  Peng Zhang,et al.  Effect of silencing NEK2 on biological behaviors of HepG2 in human hepatoma cells and MAPK signal pathway , 2016, Tumor Biology.

[9]  Lei Lu,et al.  Clinical significance and prognostic value of Nek2 protein expression in colon cancer. , 2015, International journal of clinical and experimental pathology.

[10]  W. Zhong,et al.  Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer , 2015, BMC Urology.

[11]  N. Ringstad,et al.  Nek2 activation of Kif24 ensures cilium disassembly during the cell cycle , 2015, Nature Communications.

[12]  Teruhiko Yoshida,et al.  Alterations of the spindle checkpoint pathway in clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas , 2015, International journal of cancer.

[13]  Benjamin Geiger,et al.  Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant. , 2015, The Journal of clinical investigation.

[14]  F. Zhan,et al.  Role of NEK2A in Human Cancer and Its Therapeutic Potentials , 2015, BioMed research international.

[15]  A. Fry,et al.  Overexpression of the Nek2 kinase in colorectal cancer correlates with beta‐catenin relocalization and shortened cancer‐specific survival , 2014, Journal of surgical oncology.

[16]  F. Zhan,et al.  Inhibition of Nek2 by Small Molecules Affects Proteasome Activity , 2014, BioMed research international.

[17]  F. Zhan,et al.  NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma , 2014, Oncotarget.

[18]  Wenke Liu,et al.  Aberrant expression of NEK2 and its clinical significance in non-small cell lung cancer , 2014, Oncology letters.

[19]  R. Gish,et al.  Inhibition of Hec1 as a novel approach for treatment of primary liver cancer , 2014, Cancer Chemotherapy and Pharmacology.

[20]  Yu-Hsiang Lin,et al.  Discovery of 4-aryl-N-arylcarbonyl-2-aminothiazoles as Hec1/Nek2 inhibitors. Part I: optimization of in vitro potencies and pharmacokinetic properties. , 2014, Journal of medicinal chemistry.

[21]  C. Moreno,et al.  E2F Activators Signal and Maintain Centrosome Amplification in Breast Cancer Cells , 2014, Molecular and Cellular Biology.

[22]  P. Boutros,et al.  Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells , 2014, Oncogene.

[23]  Shize Yang,et al.  Examining Nek2 as a better proliferation marker in non-small cell lung cancer prognosis , 2014, Tumor Biology.

[24]  Zhong-yu Wang,et al.  Abnormal expression of Nek2 in pancreatic ductal adenocarcinoma: a novel marker for prognosis. , 2014, International journal of clinical and experimental pathology.

[25]  K. Kao,et al.  Activity of a Novel Hec1-Targeted Anticancer Compound against Breast Cancer Cell Lines In Vitro and In Vivo , 2014, Molecular Cancer Therapeutics.

[26]  Wen-Hwa Lee,et al.  Novel small molecules disrupting Hec1/Nek2 interaction ablate tumor progression by triggering Nek2 degradation through a death-trap mechanism , 2014, Oncogene.

[27]  Haiyong Han,et al.  Therapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): a perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibition. , 2014, Journal of medicinal chemistry.

[28]  K. Kao,et al.  Characterization of the biological activity of a potent small molecule Hec1 inhibitor TAI-1 , 2014, Journal of experimental & clinical cancer research : CR.

[29]  P. Chieffi,et al.  The centrosomal kinase NEK2 is a novel splicing factor kinase involved in cell survival , 2013, Nucleic acids research.

[30]  R. Cagan,et al.  Centrosomal kinase Nek2 cooperates with oncogenic pathways to promote metastasis , 2013, Oncogenesis.

[31]  M. Malumbres,et al.  A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis , 2013, Cancer cell.

[32]  A. Montag,et al.  Expression profiling of 519 kinase genes in matched malignant peripheral nerve sheath tumor/plexiform neurofibroma samples is discriminatory and identifies mitotic regulators BUB1B, PBK and NEK2 as overexpressed with transformation , 2013, Modern Pathology.

[33]  Yusuke Nakamura,et al.  Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis. , 2013, International journal of oncology.

[34]  L. Gollahon,et al.  Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple-negative breast cancer cells , 2013, International journal of oncology.

[35]  Jing Zhang,et al.  Nek2C functions as a tumor promoter in human breast tumorigenesis. , 2012, International journal of molecular medicine.

[36]  R. Bayliss,et al.  Cell cycle regulation by the NEK family of protein kinases , 2012, Journal of Cell Science.

[37]  Han Liu,et al.  Nek2A contributes to tumorigenic growth and possibly functions as potential therapeutic target for human breast cancer , 2012, Journal of cellular biochemistry.

[38]  K. Boxall,et al.  Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: structure-activity relationship, structural biology, and cellular activity. , 2012, Journal of medicinal chemistry.

[39]  Wei-dong Li,et al.  Abnormal expression of Nek2 and β‐catenin in breast carcinoma: clinicopathological correlations , 2011, Histopathology.

[40]  J. Taunton,et al.  Irreversible Nek2 kinase inhibitors with cellular activity. , 2011, Journal of medicinal chemistry.

[41]  P. Arbuthnot,et al.  Therapeutic potential of adenoviral vectors for delivery of expressed RNAi activators , 2010, Expert opinion on drug delivery.

[42]  P. Workman,et al.  Identification by High-Throughput Screening of Viridin Analogs as Biochemical and Cell-Based Inhibitors of the Cell Cycle–Regulated Nek2 Kinase , 2010, Journal of biomolecular screening.

[43]  M. Nagino,et al.  Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin , 2010, Cancer science.

[44]  R. Rosenquist,et al.  Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells , 2009, American journal of hematology.

[45]  Wen-Hwa Lee,et al.  Synthesis and biological evaluation of a series of novel inhibitor of Nek2/Hec1 analogues. , 2009, Journal of medicinal chemistry.

[46]  R. Franco,et al.  Increased expression and nuclear localization of the centrosomal kinase Nek2 in human testicular seminomas , 2009, The Journal of pathology.

[47]  M. Nagino,et al.  Nek2 as a novel molecular target for the treatment of breast carcinoma , 2009, Cancer science.

[48]  Phang-lang Chen,et al.  Small molecule targeting the Hec1/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal. , 2008, Cancer research.

[49]  S. Wacholder,et al.  Gene Expression Signature of Cigarette Smoking and Its Role in Lung Adenocarcinoma Development and Survival , 2008, PloS one.

[50]  L. Ozbun,et al.  Cell Cycle and Related Protein , 2007, Disease markers.

[51]  P. Comoglio,et al.  The MET receptor tyrosine kinase in invasion and metastasis , 2007, Journal of cellular physiology.

[52]  M. Nagino,et al.  Nek2 as an effective target for inhibition of tumorigenic growth and peritoneal dissemination of cholangiocarcinoma. , 2007, Cancer research.

[53]  E. F. da Cruz e Silva,et al.  Alternative Splicing Controls Nuclear Translocation of the Cell Cycle-regulated Nek2 Kinase* , 2007, Journal of Biological Chemistry.

[54]  Stefan Knapp,et al.  Structure and Regulation of the Human Nek2 Centrosomal Kinase* , 2007, Journal of Biological Chemistry.

[55]  P. Comoglio,et al.  Invasive growth: a MET-driven genetic programme for cancer and stem cells , 2006, Nature Reviews Cancer.

[56]  A. Fry,et al.  Nek2 kinase in chromosome instability and cancer. , 2006, Cancer letters.

[57]  P. Nelson,et al.  CaSm-mediated cellular transformation is associated with altered gene expression and messenger RNA stability. , 2005, Cancer research.

[58]  R. Muschel,et al.  Live cell imaging reveals distinct roles in cell cycle regulation for Nek2A and Nek2B. , 2005, Biochimica et biophysica acta.

[59]  Andrew M Fry,et al.  The Centrosomal Kinase Nek2 Displays Elevated Levels of Protein Expression in Human Breast Cancer , 2004, Cancer Research.

[60]  Xia Ding,et al.  Nek2A kinase regulates the localization of numatrin to centrosome in mitosis , 2004, FEBS letters.

[61]  T. Grogan,et al.  Gene Expression Profile of Serial Samples of Transformed B-Cell Lymphomas , 2003, Laboratory Investigation.

[62]  D. Riley,et al.  Phosphorylation of the Mitotic Regulator Protein Hec1 by Nek2 Kinase Is Essential for Faithful Chromosome Segregation* , 2002, The Journal of Biological Chemistry.

[63]  Toshifumi Ozaki,et al.  Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays. , 2002, International journal of oncology.

[64]  A. Fry,et al.  APC/C‐mediated destruction of the centrosomal kinase Nek2A occurs in early mitosis and depends upon a cyclin A‐type D‐box , 2001, The EMBO journal.

[65]  N. Sagata,et al.  Nek2B, a novel maternal form of Nek2 kinase, is essential for the assembly or maintenance of centrosomes in early Xenopus embryos , 2000, The EMBO journal.

[66]  M. Kirschner,et al.  The KEN box: an APC recognition signal distinct from the D box targeted by Cdh1. , 2000, Genes & development.

[67]  E. Nigg,et al.  Activity of the Human Centrosomal Kinase, Nek2, Depends on an Unusual Leucine Zipper Dimerization Motif* , 1999, The Journal of Biological Chemistry.

[68]  N. Sagata,et al.  Two structural variants of Nek2 kinase, termed Nek2A and Nek2B, are differentially expressed in Xenopus tissues and development. , 1999, Developmental biology.

[69]  P. Meraldi,et al.  C-Nap1, a Novel Centrosomal Coiled-Coil Protein and Candidate Substrate of the Cell Cycle–regulated Protein Kinase Nek2 , 1998, The Journal of cell biology.

[70]  T. Ried,et al.  Cell cycle-dependent expression of Nek2, a novel human protein kinase related to the NIMA mitotic regulator of Aspergillus nidulans. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[71]  H. Saavedra,et al.  Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance. , 2014, Frontiers in bioscience.

[72]  B. Cheng,et al.  Identified differently expressed genes in renal cell carcinoma by using multiple microarray datasets running head: differently expressed genes in renal cell carcinoma. , 2014, European review for medical and pharmacological sciences.

[73]  P. Chieffi Recent advances in molecular and cell biology of testicular germ-cell tumors. , 2014, International review of cell and molecular biology.

[74]  F. Zhan,et al.  NEK 2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers , 2013 .

[75]  H. Nagai,et al.  cDNA Array Analysis for Prediction of Hepatic Metastasis of Colorectal Carcinoma , 2006, Surgery Today.

[76]  P. Meraldi,et al.  C-Nap 1 , a Novel Centrosomal Coiled-Coil Protein and Candidate Substrate of the Cell Cycle – regulated Protein Kinase Nek 2 , 1998 .